Silicon Therapeutics Report issue

For profit Phase 1
Founded: Boston MA United States (2016)
Status: Acquired by Roivant Sciences, Inc. (2021) → now Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial
2020
NCT04609579
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Silicon Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (2)

pembrolizumab (keytruda) (1 trial)

snx281 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2